X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (42) 42
humans (40) 40
male (40) 40
female (35) 35
middle aged (27) 27
aged (25) 25
adult (22) 22
chemotherapy (19) 19
care and treatment (18) 18
lung cancer (16) 16
oncology (16) 16
lung neoplasms - drug therapy (13) 13
cancer (12) 12
analysis (11) 11
hematology, oncology and palliative medicine (11) 11
lung cancer, non-small cell (11) 11
lung neoplasms - pathology (11) 11
neoplasm staging (11) 11
prognosis (11) 11
treatment outcome (11) 11
carcinoma, non-small-cell lung - drug therapy (10) 10
mutation (10) 10
aged, 80 and over (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
japan (9) 9
medical research (9) 9
animals (8) 8
cancer therapies (8) 8
metastasis (8) 8
survival (8) 8
clinical trials (7) 7
research (7) 7
respiratory system (7) 7
trial (7) 7
tumors (7) 7
clinical neurology (6) 6
lung neoplasms - mortality (6) 6
medical colleges (6) 6
medicine, experimental (6) 6
metaanalysis (6) 6
patients (6) 6
abridged index medicus (5) 5
carcinoma, non-small-cell lung - genetics (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
diagnosis (5) 5
expression (5) 5
follow-up studies (5) 5
health aspects (5) 5
lung cancer, small cell (5) 5
lung neoplasms - genetics (5) 5
magnetic resonance imaging (5) 5
rats (5) 5
safety (5) 5
tyrosine (5) 5
usage (5) 5
carcinoma (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
cardiac & cardiovascular systems (4) 4
college teachers (4) 4
combination (4) 4
confidence intervals (4) 4
docetaxel (4) 4
gefitinib (4) 4
iii trial (4) 4
immunotherapy (4) 4
medicine & public health (4) 4
medicine, general & internal (4) 4
motivation (4) 4
multicenter (4) 4
neurosciences (4) 4
nsclc (4) 4
protein-tyrosine kinase (4) 4
pulmonary/respiratory (4) 4
radiotherapy (4) 4
rats, sprague-dawley (4) 4
risk factors (4) 4
small cell lung carcinoma - pathology (4) 4
solid tumors (4) 4
survival analysis (4) 4
therapy (4) 4
antineoplastic agents - therapeutic use (3) 3
apoptosis (3) 3
biomarkers (3) 3
child (3) 3
cisplatin - administration & dosage (3) 3
cohort studies (3) 3
disease control (3) 3
disease-free survival (3) 3
dna mutational analysis (3) 3
drug administration schedule (3) 3
epidermal growth factor receptors (3) 3
erlotinib (3) 3
etoposide (3) 3
gene expression (3) 3
gene rearrangement (3) 3
genes (3) 3
genetic aspects (3) 3
genetic disorders (3) 3
immunohistochemistry (3) 3
infant, newborn (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | GEFITINIB | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 1, pp. 42 - 50
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 99, pp. 186 - 193
Journal Article
Human Pathology, ISSN 0046-8177, 2014, Volume 45, Issue 5, pp. 1045 - 1056
Journal Article